# Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Study · id `cardio:ct-nct01267448` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01267448](<https://clinicaltrials.gov/study/NCT01267448>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01267448

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01267448. Randomized; no masking; primary purpose treatment. Start 2014-09-09 (actual); primary completion 2015-07-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01267448, source copy `cardio:ctgov-nct01267448-2023-06-26`, retrieved 2026-10-26)
- Started: 2014-09-09 (actual) (ClinicalTrials.gov record NCT01267448, source copy `cardio:ctgov-nct01267448-2023-06-26`, retrieved 2026-10-26)
- Primary completion: 2015-07-25 (actual) (ClinicalTrials.gov record NCT01267448, source copy `cardio:ctgov-nct01267448-2023-06-26`, retrieved 2026-10-26)
- Completion: 2015-07-25 (actual) (ClinicalTrials.gov record NCT01267448, source copy `cardio:ctgov-nct01267448-2023-06-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01267448, source copy `cardio:ctgov-nct01267448-2023-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01267448-2023-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
- Condition: Diabetes Mellitus Type 2
- Condition: Hyperglycemia
- Intervention (Drug): Glipizide XL
- Intervention (Drug): Saxagliptin + Metformin XR
- Intervention (Drug): Metformin XR
- Lead sponsor: Cook County Health
- Lead sponsor class: OTHER\_GOV
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Cook County Health (`cardio:org-cook-county-health`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

## Provenance

Content hash: 9342ff6ed8679f29a38e6eb8d46cdfbdb1c573e93313775cb9679f482afbde8e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
